Orchestrating the immune Response
TO DEFEAT CANCER

Engineering precision immunity

Elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent Amphiphile immunotherapies including cell therapy activators, immunomodulators, and vaccines to defeat an array of aggressive cancers.

»LEARN MORE

Lymph nodes:
where the immune response is orchestrated


Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine, Ph.D., a Howard Hughes Medical Institute investigator and professor at the Koch Institute of Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio’s Amphiphiles target and concentrate in the lymph nodes, resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.  Elicio is developing this approach to deliver next generation therapies, with lead programs in KRAS-driven cancers and CAR-T cell activators for CD19, BCMA, and multiple solid cancers. 

» LEARN MORE

 

 

NEXT-GENERATION IMMUNO-ONCOLOGY PLATFORM

Our programs

Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2020. This program consists of an Amphiphile vaccine that has the potential to elicit powerful immune responses against KRAS, a mutation found in 90% of pancreatic cancers, and 40% of colorectal cancers.

»LEARN MORE

»VIEW OUR PIPELINE

Latest News

BioCentury: Elicio vaccine targets oncogenic KRAS mutations
Elicio Therapeutics (Cambridge, Mass.) showed its ELI-002 vaccine generated immune responses against all common KRAS mutations, resulting in cytolytic activity against cells expressing the mutations. » Read more
Elicio Therapeutics Presents In Vivo Data for a Universal Amphiphile Vaccine Targeting KRAS-Driven Cancers
Demonstrates robust immune responses and cytolytic activity targeting the seven key mKRAS mutations CAMBRIDGE MA., AUGUST 7th, 2019 (BusinessWire) – Phase One patient data from a potential therapy targeting a single KRAS mutation, formerly considered “undruggable,” has been introduced in 2019. Now, Elicio Therapeutics, a next generation immuno-oncology company, is presenting significant preclinical data from a novel lymph-node […] » Read more